The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Imbruvica is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.
The global Imbruvica market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Imbruvica is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Imbruvica is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Imbruvica in Mantle Cell Lymphoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Imbruvica include AbbVie (Pharmacyclics), Johnson & Johnson (Janssen Biotech) and SP Laboratories, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Imbruvica, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Imbruvica.
Report Scope
The Imbruvica market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Imbruvica market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Imbruvica companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie (Pharmacyclics)
Johnson & Johnson (Janssen Biotech)
SP Laboratories
Segment by Type
5 mg
10 mg
140 mg
Segment by Application
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia
Waldenström's Macroglobulinemia
Relapsed/Refractory Marginal Zone Lymphoma
Chronic Graft-Versus-Host-Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Imbruvica companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Imbruvica is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.
The global Imbruvica market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Imbruvica is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Imbruvica is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Imbruvica in Mantle Cell Lymphoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Imbruvica include AbbVie (Pharmacyclics), Johnson & Johnson (Janssen Biotech) and SP Laboratories, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Imbruvica, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Imbruvica.
Report Scope
The Imbruvica market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Imbruvica market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Imbruvica companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie (Pharmacyclics)
Johnson & Johnson (Janssen Biotech)
SP Laboratories
Segment by Type
5 mg
10 mg
140 mg
Segment by Application
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia
Waldenström's Macroglobulinemia
Relapsed/Refractory Marginal Zone Lymphoma
Chronic Graft-Versus-Host-Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Imbruvica companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Imbruvica Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 5 mg
1.2.3 10 mg
1.2.4 140 mg
1.3 Market by Application
1.3.1 Global Imbruvica Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Mantle Cell Lymphoma
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 Waldenström's Macroglobulinemia
1.3.5 Relapsed/Refractory Marginal Zone Lymphoma
1.3.6 Chronic Graft-Versus-Host-Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Imbruvica Market Perspective (2019-2030)
2.2 Imbruvica Growth Trends by Region
2.2.1 Global Imbruvica Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Imbruvica Historic Market Size by Region (2019-2024)
2.2.3 Imbruvica Forecasted Market Size by Region (2025-2030)
2.3 Imbruvica Market Dynamics
2.3.1 Imbruvica Industry Trends
2.3.2 Imbruvica Market Drivers
2.3.3 Imbruvica Market Challenges
2.3.4 Imbruvica Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Imbruvica Players by Revenue
3.1.1 Global Top Imbruvica Players by Revenue (2019-2024)
3.1.2 Global Imbruvica Revenue Market Share by Players (2019-2024)
3.2 Global Imbruvica Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Imbruvica Revenue
3.4 Global Imbruvica Market Concentration Ratio
3.4.1 Global Imbruvica Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Imbruvica Revenue in 2023
3.5 Imbruvica Key Players Head office and Area Served
3.6 Key Players Imbruvica Product Solution and Service
3.7 Date of Enter into Imbruvica Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Imbruvica Breakdown Data by Type
4.1 Global Imbruvica Historic Market Size by Type (2019-2024)
4.2 Global Imbruvica Forecasted Market Size by Type (2025-2030)
5 Imbruvica Breakdown Data by Application
5.1 Global Imbruvica Historic Market Size by Application (2019-2024)
5.2 Global Imbruvica Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Imbruvica Market Size (2019-2030)
6.2 North America Imbruvica Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Imbruvica Market Size by Country (2019-2024)
6.4 North America Imbruvica Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Imbruvica Market Size (2019-2030)
7.2 Europe Imbruvica Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Imbruvica Market Size by Country (2019-2024)
7.4 Europe Imbruvica Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Imbruvica Market Size (2019-2030)
8.2 Asia-Pacific Imbruvica Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Imbruvica Market Size by Region (2019-2024)
8.4 Asia-Pacific Imbruvica Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Imbruvica Market Size (2019-2030)
9.2 Latin America Imbruvica Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Imbruvica Market Size by Country (2019-2024)
9.4 Latin America Imbruvica Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Imbruvica Market Size (2019-2030)
10.2 Middle East & Africa Imbruvica Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Imbruvica Market Size by Country (2019-2024)
10.4 Middle East & Africa Imbruvica Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie (Pharmacyclics)
11.1.1 AbbVie (Pharmacyclics) Company Detail
11.1.2 AbbVie (Pharmacyclics) Business Overview
11.1.3 AbbVie (Pharmacyclics) Imbruvica Introduction
11.1.4 AbbVie (Pharmacyclics) Revenue in Imbruvica Business (2019-2024)
11.1.5 AbbVie (Pharmacyclics) Recent Development
11.2 Johnson & Johnson (Janssen Biotech)
11.2.1 Johnson & Johnson (Janssen Biotech) Company Detail
11.2.2 Johnson & Johnson (Janssen Biotech) Business Overview
11.2.3 Johnson & Johnson (Janssen Biotech) Imbruvica Introduction
11.2.4 Johnson & Johnson (Janssen Biotech) Revenue in Imbruvica Business (2019-2024)
11.2.5 Johnson & Johnson (Janssen Biotech) Recent Development
11.3 SP Laboratories
11.3.1 SP Laboratories Company Detail
11.3.2 SP Laboratories Business Overview
11.3.3 SP Laboratories Imbruvica Introduction
11.3.4 SP Laboratories Revenue in Imbruvica Business (2019-2024)
11.3.5 SP Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
